Drug Profile
Research programme: SARS-coronavirus antibodies - Diversa
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Diversa
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coronavirus-infections in USA (Parenteral)
- 14 Sep 2004 Preclinical trials in Coronavirus infections in USA (unspecified route)